A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting

Phase 3

VedolizumabA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Sponsor:

Takeda

Code:

NCT05442567

Conditions

Ulcerative Colitis

Crohn's Disease

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Not accepted

Interventions

Vedolizumab IV

No Intervention

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-14. This information was provided to ClinicalTrials.gov by Takeda on 2025-04-09.